Aegis set a $17.00 price objective on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) in a research note issued to investors on Friday. The firm currently has a hold rating on the biotechnology company’s stock.
A number of other brokerages have also commented on MNTA. J P Morgan Chase & Co reissued a buy rating and issued a $18.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, November 3rd. Barclays PLC reaffirmed a buy rating and set a $19.00 price target on shares of Momenta Pharmaceuticals in a research report on Thursday, November 3rd. Stifel Nicolaus set a $20.00 price target on shares of Momenta Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, November 29th. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a hold rating to a buy rating and set a $15.00 price target on the stock in a research report on Friday, November 11th. Finally, Maxim Group reaffirmed a sell rating and set a $6.00 price target on shares of Momenta Pharmaceuticals in a research report on Thursday, November 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. Momenta Pharmaceuticals presently has an average rating of Hold and a consensus target price of $16.30.
Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 3.41% on Friday, reaching $15.60. 227,390 shares of the company were exchanged. The stock has a 50 day moving average of $14.70 and a 200 day moving average of $12.45. Momenta Pharmaceuticals has a 12-month low of $7.86 and a 12-month high of $17.25. The firm’s market capitalization is $1.08 billion.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative net margin of 93.75% and a negative return on equity of 26.55%. The firm had revenue of $299.14 million for the quarter, compared to analyst estimates of $25.68 million. During the same quarter in the previous year, the firm posted ($0.44) earnings per share. The business’s revenue was up 2067.7% on a year-over-year basis. Equities analysts anticipate that Momenta Pharmaceuticals will post ($1.18) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Aegis Analysts Give Momenta Pharmaceuticals, Inc. (MNTA) a $17.00 Price Target” was originally published by Community Financial News and is the propert of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/01/11/aegis-analysts-give-momenta-pharmaceuticals-inc-mnta-a-17-00-price-target.html.
In related news, CFO Richard P. Shea sold 9,799 shares of the company’s stock in a transaction dated Thursday, December 15th. The shares were sold at an average price of $15.00, for a total transaction of $146,985.00. Following the completion of the sale, the chief financial officer now owns 121,972 shares of the company’s stock, valued at $1,829,580. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Craig A. Wheeler sold 5,880 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $13.68, for a total transaction of $80,438.40. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA boosted its stake in Momenta Pharmaceuticals by 115.4% in the second quarter. BNP Paribas Arbitrage SA now owns 19,816 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 10,617 shares in the last quarter. Capstone Asset Management Co. boosted its stake in Momenta Pharmaceuticals by 3.6% in the second quarter. Capstone Asset Management Co. now owns 18,183 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 630 shares in the last quarter. Hartford Investment Management Co. purchased a new stake in Momenta Pharmaceuticals during the second quarter valued at $160,000. New York State Teachers Retirement System boosted its stake in Momenta Pharmaceuticals by 0.3% in the second quarter. New York State Teachers Retirement System now owns 93,675 shares of the biotechnology company’s stock valued at $1,012,000 after buying an additional 300 shares in the last quarter. Finally, ClariVest Asset Management LLC boosted its stake in Momenta Pharmaceuticals by 15.6% in the second quarter. ClariVest Asset Management LLC now owns 32,613 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 4,400 shares in the last quarter. 84.60% of the stock is owned by institutional investors and hedge funds.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).
What are top analysts saying about Momenta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Momenta Pharmaceuticals Inc. and related companies.